RxDoctor Payments Data

Hoai-Huong Huynh, NP

Nurse Practitioner · San Diego, CANPI 1194035501

Payments from drug & device makers

$1,847in general payments, 2019–2025

Across 39 payments — averaging $47.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$584
  • Boston Scientific$400
  • Kyowa Kirin, Inc.$390
  • AbbVie$240
  • Sunovion Pharmaceuticals Inc.$72
  • Acadia Pharmaceuticals Inc$70
  • plus $93 from 2 others

What the payments were for

  • Consulting fees$96552%
  • Food & beverage$88248%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,847 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$142,584
Medicare patients
409
Services billed
1,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa566$1,315,688
NuplazidPimavanserin Tartrate138$1,042,730
AustedoDeutetrabenazine21$215,974
GocovriAmantadine Hcl38$176,540
Droxidopa140$160,464
MyrbetriqMirabegron66$68,691
Carbidopa86$63,663
NeuproRotigotine36$48,639
Carbidopa-LevodopaCarbidopa/Levodopa628$39,770
XadagoSafinamide Mesylate19$39,635
Rasagiline Mesylate170$35,986
Rivastigmine111$35,472
Midodrine Hcl135$23,483
Carbidopa-Levodopa ErCarbidopa/Levodopa198$22,320
LinzessLinaclotide14$20,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$70$1,042,730138 claims
AbbVieLinzess$240$20,10914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →